title: Clopidogrel: a selective inhibitor of platelet ADP receptors.
abstract: Platelets play a key role in the development of ischemic complications in the arterial circulation. Antiplatelet therapy has proven effective in the treatment and prevention of ischemic events. Numerous clinical studies have confirmed the therapeutic efficacy of aspirin to such a point that this antiplatelet agent has become the gold standard in clinical practice. Clopidogrel is a thienopyridine compound that inhibits platelet aggregation by selectively binding to adenylate cyclase-coupled ADP receptors. Results of a large, double-blind, randomized study (CAPRIE) confirm that administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischemic stroke, myocardial infarction or vascular death. The present article highlights the importance of activation of platelets through ADP receptors and reviews the pharmacology and clinical studies of clopidogrel, a selective inhibitor of these mechanisms.
authors.affiliation: Hemotherapy and Hemostasis Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Escolar
authors.forename: M
authors.initials: M
authors.lastname: Heras